NLS Pharmaceutics Shareholders Approve All Agenda Items
Ticker: NCEL · Form: 6-K · Filed: Sep 19, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, filing
Related Tickers: NLS
TL;DR
NLS Pharma shareholders greenlit everything at the Sept 18 meeting.
AI Summary
NLS Pharmaceutics Ltd. held an extraordinary shareholders' meeting on September 18, 2024, where all proposed agenda items were approved. The company is a foreign private issuer filing a Report of Foreign Private Issuer (Form 6-K) for the month of September 2024.
Why It Matters
Shareholder approval of all agenda items suggests smooth governance and potential progress on the company's strategic initiatives.
Risk Assessment
Risk Level: low — The filing reports routine shareholder meeting outcomes with no new financial or operational risks disclosed.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- September 18, 2024 (date) — Date of extraordinary shareholders' meeting
- Form 6-K (document) — Type of SEC filing
- Form F-3 (document) — Incorporated registration statements
FAQ
What was the outcome of the extraordinary shareholders' meeting held by NLS Pharmaceutics Ltd. on September 18, 2024?
All agenda items as originally proposed were approved by the shareholders at the meeting.
What type of SEC filing is this report?
This is a Report of Foreign Private Issuer on Form 6-K.
For which month is this Form 6-K report being filed?
The report is for the month of September 2024.
What are the file numbers for the NLS Pharmaceutics Ltd. Registration Statements on Form F-3 that are incorporated by reference?
The incorporated registration statements have file numbers 333-262489 and 333-268690.
Where is NLS Pharmaceutics Ltd. located?
NLS Pharmaceutics Ltd. is located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 245 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-09-19 16:01:12
Filing Documents
- ea0215086-6k_nlspharma.htm (6-K) — 10KB
- 0001213900-24-080258.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 19, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2